Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiangiogenic therapy in hematologic malignancies.

T M Moehler1, J Hillengass, H Goldschmidt

  • 1University of Heidelberg, Dept. of Internal Medicine V, Heidelberg, FRG. Thomas_Moehler@med.uni-heidelberg.de

Current Pharmaceutical Design
|April 14, 2004
PubMed
Summary

Angiogenesis, the growth of new blood vessels, is crucial in blood cancers. Targeting angiogenesis with drugs like thalidomide shows promise for treating hematologic malignancies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

An automated approach to determine antibody endpoint titers for COVID-19 by an enzyme-linked immunosorbent assay.

Immunohematology·2021
Same author

Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD.

Bone marrow transplantation·2017
Same author

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.

BMC cancer·2017
Same author

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.

Oncogenesis·2017
Same author

GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.

Bone marrow transplantation·2017

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Angiogenesis, the formation of new capillaries from existing vessels, is vital in the progression of solid tumors and hematologic malignancies.
  • Markers of angiogenesis correlate with clinical characteristics in leukemia and non-Hodgkin's lymphoma, predicting poor prognosis.

Purpose of the Study:

  • To explore the role of angiogenesis in hematologic malignancies.
  • To evaluate the therapeutic potential of antiangiogenic drugs in treating these cancers.

Main Methods:

  • Review of existing literature on angiogenesis markers and antiangiogenic therapies.
  • Analysis of clinical data correlating angiogenic markers with treatment response.

Main Results:

Related Experiment Videos

  • Antiangiogenic effects of chemotherapeutics, farnesyltransferase inhibitors, and tyrosine kinase inhibitors (e.g., Gleevec) may contribute to their therapeutic efficacy.
  • Thalidomide demonstrates effectiveness in multiple myeloma and myelodysplastic syndrome (MDS), improving cytopenia and transfusion independence.
  • Preliminary data suggest activity of VEGF receptor tyrosine kinase (RTK) inhibitors in multiple myeloma (MM) and acute myeloid leukemia (AML).

Conclusions:

  • Increased levels of angiogenic cytokines correlate with clinical response to VEGF-RTK inhibitors and thalidomide, highlighting the importance of identifying patients who will benefit from these targeted approaches.
  • Incorporating antiangiogenic drugs into treatment protocols for hematologic malignancies warrants further investigation in future clinical studies.